The role of the gut microbiome in gastrointestinal cancers
Copyright © 2023. Published by Elsevier Inc..
The gut microbiota present in the human digestive system is incredibly varied and is home to trillions of microorganisms. The gut microbiome is shaped at birth, while numerous genetic, dietary, and environmental variables primarily influence the microbiome composition. The importance of gut microbiota on host health is becoming more widely acknowledged. Digestion, intestinal permeability, and immunological and metabolism responses can all be affected by changes in the composition and function of the gut microbiota. There is mounting evidence that the microbial population's complex traits are important biomarkers and indicators of patient outcomes in cancer and its therapies. Numerous studies have demonstrated that changed commensal gut microorganisms contribute to the development and spread of cancer through various routes. Despite the ongoing controversy surrounding the gut microbiome and gastrointestinal cancer, accumulating evidence points to a potentially far more intricate connection than a simple cause-and-effect relationship. SIMPLE SUMMARY: Due to their high frequency and fatality rate, gastrointestinal cancers are regarded as a severe public health issue with complex medical and economic burdens. The gut microbiota may directly or indirectly interact with existing therapies like immunotherapy and chemotherapy, affecting how well a treatment works. The gut microbiome influences the immune response's activity, function, and development. Generally, certain gut bacteria impact the antitumor actions during cancer by creating particular metabolites or triggering T-cell responses. Yet, certain bacterial species have been found to promote cellular proliferation and metastasis in cancer, and comprehending these interactions in the context of cancer may help identify possible treatment targets. Notwithstanding the improvements in the field, additional research is still required to comprehend the underlying processes, examine the effects on existing therapies, and pinpoint certain bacteria and immune cells that can cause this interaction.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:115 |
|---|---|
| Enthalten in: |
Cellular signalling - 115(2024) vom: 21. März, Seite 111013 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mishra, Yachana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Gastrointestinal cancer |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cellsig.2023.111013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366046497 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366046497 | ||
| 003 | DE-627 | ||
| 005 | 20240323234843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cellsig.2023.111013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1342.xml |
| 035 | |a (DE-627)NLM366046497 | ||
| 035 | |a (NLM)38113978 | ||
| 035 | |a (PII)S0898-6568(23)00428-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mishra, Yachana |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of the gut microbiome in gastrointestinal cancers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a The gut microbiota present in the human digestive system is incredibly varied and is home to trillions of microorganisms. The gut microbiome is shaped at birth, while numerous genetic, dietary, and environmental variables primarily influence the microbiome composition. The importance of gut microbiota on host health is becoming more widely acknowledged. Digestion, intestinal permeability, and immunological and metabolism responses can all be affected by changes in the composition and function of the gut microbiota. There is mounting evidence that the microbial population's complex traits are important biomarkers and indicators of patient outcomes in cancer and its therapies. Numerous studies have demonstrated that changed commensal gut microorganisms contribute to the development and spread of cancer through various routes. Despite the ongoing controversy surrounding the gut microbiome and gastrointestinal cancer, accumulating evidence points to a potentially far more intricate connection than a simple cause-and-effect relationship. SIMPLE SUMMARY: Due to their high frequency and fatality rate, gastrointestinal cancers are regarded as a severe public health issue with complex medical and economic burdens. The gut microbiota may directly or indirectly interact with existing therapies like immunotherapy and chemotherapy, affecting how well a treatment works. The gut microbiome influences the immune response's activity, function, and development. Generally, certain gut bacteria impact the antitumor actions during cancer by creating particular metabolites or triggering T-cell responses. Yet, certain bacterial species have been found to promote cellular proliferation and metastasis in cancer, and comprehending these interactions in the context of cancer may help identify possible treatment targets. Notwithstanding the improvements in the field, additional research is still required to comprehend the underlying processes, examine the effects on existing therapies, and pinpoint certain bacteria and immune cells that can cause this interaction | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Gastrointestinal cancer | |
| 650 | 4 | |a Gut microbiota | |
| 650 | 4 | |a Liver cancer | |
| 650 | 4 | |a Microbes | |
| 650 | 4 | |a Microbiome | |
| 700 | 1 | |a Ranjan, Abhigyan |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Chattaraj, Aditi |e verfasserin |4 aut | |
| 700 | 1 | |a Aljabali, Alaa A A |e verfasserin |4 aut | |
| 700 | 1 | |a El-Tanani, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Hromić-Jahjefendić, Altijana |e verfasserin |4 aut | |
| 700 | 1 | |a Uversky, Vladimir N |e verfasserin |4 aut | |
| 700 | 1 | |a Tambuwala, Murtaza M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular signalling |d 1993 |g 115(2024) vom: 21. März, Seite 111013 |w (DE-627)NLM012637653 |x 1873-3913 |7 nnns |
| 773 | 1 | 8 | |g volume:115 |g year:2024 |g day:21 |g month:03 |g pages:111013 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cellsig.2023.111013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 115 |j 2024 |b 21 |c 03 |h 111013 | ||